An­i­mal health vet Juer­gen Horn makes new an­ti­body play for pets, rak­ing $15M in Se­ries A haul

Zoetis forked over $85 mil­lion in 2017 to ac­quire Nexvet Bio­phar­ma and its pipeline of mon­o­clon­al an­ti­bod­ies. Juer­gen Horn, Nexvet’s for­mer chief prod­uct de­vel­op­ment of­fi­cer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER